Open AccessDurable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
Author(s) -
Ma del Carmen Álamo,
Sebastián Ochenduszko,
Guillermo Crespo,
Mónica Corral,
Juana Oramas,
Pilar Sancho,
J. Sáenz Medina,
Fernando Garicano,
Pedro López,
Begoña CamposBalea,
Analia Rodríguez Garzotto,
Eva MuñozCouselo
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s325208
Subject(s) - vemurafenib , medicine , oncology , surgery , metastatic melanoma , cancer
The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobimetinib in terms of durability, and to describe differential characteristics in patients associated to durable responses in real-world settings.